StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note published on Sunday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Down 3.3 %

Shares of Brooklyn ImmunoTherapeutics stock opened at $1.77 on Friday. The firm’s 50 day simple moving average is $2.11 and its two-hundred day simple moving average is $1.79. The firm has a market capitalization of $104.12 million, a price-to-earnings ratio of -0.78 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 12-month low of $0.17 and a 12-month high of $10.10.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.